Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

834.04
+7.400.90%
Post-market: 834.040.00000.00%19:58 EDT
Volume:786.92K
Turnover:656.91M
Market Cap:85.87B
PE:20.63
High:847.00
Open:835.74
Low:826.64
Close:826.64
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.27
T/O Rate:0.80%
Dividend:3.64
Dividend Rate:0.44%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.71
PE(LYR):20.11

Loading ...

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
May 30

Regeneron Advances Phase 3 ROXI-CAT-II Trial, Targeting Safer Cancer-Related Clot Treatment

TIPRANKS
·
May 30

FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development

Reuters
·
May 29

Regeneron Treatment for Ebola Recommended for Priority Evaluation by WHO

Dow Jones
·
May 29

Regeneron Ebola antibody recommended by WHO for investigational use

TIPRANKS
·
May 29

Regeneron Pharmaceuticals Inc: Maftivimab Shown Broad Activity in Vitro Against Multiple Ebola Species, Including Bundibugyo

THOMSON REUTERS
·
May 29

Regeneron Pharmaceuticals Inc - Supply of Inmazeb Is Already on Ground in Drc

THOMSON REUTERS
·
May 29

Regeneron Pharmaceuticals - Preparing Maftivimab Supply for Clinical Trials; Inmazeb Available in Drc

THOMSON REUTERS
·
May 29

Regeneron Pharmaceuticals Inc: Maftivimab Has Been Recommended to Be Studied as a Monotherapy in Current Outbreak

THOMSON REUTERS
·
May 29

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

THOMSON REUTERS
·
May 29

WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak

Reuters
·
May 29

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
May 28

A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership

Simply Wall St.
·
May 26

US Biotech Regeneron to Launch Global Capability Centre in India's Hyderabad - Statement

THOMSON REUTERS
·
May 26

Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal Scrutiny - And What's Next

Simply Wall St.
·
May 24

Regeneron, Circle, Burlington, Ross, Pembina Trending With Analysts

TIPRANKS
·
May 23

FACTBOX-Bundibugyo Ebola vaccines and treatments in development

Reuters
·
May 23

Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment

MT Newswires Live
·
May 22

EMA accepts Regeneron Otarmeni gene therapy filing for OTOF-related hearing loss review

Reuters
·
May 22

BRIEF-Otarmeni Receives EMA Filing Acceptance For Genetic Hearing Loss

Reuters
·
May 22